NCT00005817View on ClinicalTrials.gov

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 31, 2000

Primary Completion Date

May 31, 2006

Conditions
Male Breast CancerRecurrent Breast CancerStage IIIB Breast CancerStage IV Breast Cancer
Interventions
DRUG

becatecarin

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005817 - Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter